Claims for Patent: 5,639,480
✉ Email this page to a colleague
Summary for Patent: 5,639,480
| Title: | Sustained release formulations of water soluble peptides |
| Abstract: | The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide)glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer. |
| Inventor(s): | Bodmer; David (Klingnau, CH), Fong; Jones W. (Parsippany, NJ), Kissel; Thomas (Staufen, DE), Maulding; Hawkins V. (Mendham, NJ), Nagele; Oskar (Sissach, CH), Pearson; Jane E. (Ogendensburg, NJ) |
| Assignee: | Sandoz Ltd. (Basel, CH) |
| Application Number: | 08/470,072 |
| Patent Claims: |
1. A microparticle having a diameter of between 1 and 250 microns comprising octreotide, in a free base, acid addition salt or complex form in a biodegradable, biocompatible
polymeric matrix of a 40/60 to 60/40 polylactide-co-glycolide ester of a polyol, said polyol being selected from the group consisting of 1) a (C.sub.3-6) carbon chain containing alcohol having 3 to 6 hydroxyl groups, 2) a mono-saccharide and 3) a
di-saccharide, and said esterified polyol having at least 3 polylactide-co-glycolide chains, wherein said octreotide is present in a therapeutically effective amount from at least 0.2 percent by weight relative to said polymeric matrix and said
octreotide is distributed throughout said polymeric matrix.
2. A microparticle according to claim 1 wherein the octreotide is in a polymeric matrix of poly(D,L-lactide co-glycolide)glucose. 3. A sustained release formulation comprising a microparticle of claim 2. 4. A sustained release formulation according to claim 3 which when administered subcutaneously to a rat at a dosage of 10 mg of octreotide per kg of body weight exhibits an octreotide concentration in the blood plasma of at least 0.3 ng/ml and less than 20 ng/ml during a 30 day term. 5. A sustained release formulation according to claim 3 which when administered to a rabbit intramuscularly at a dosage of 5 mg of octreotide per kg of body weight exhibits an octreotide concentration of at least 0.3 ng/ml and at most 20 ng/ml during a 50 day term. 6. A sustained release formulation according to claim 3 which when administered to a rabbit intramuscularly at a dosage of 5 mg of octreotide per kg of body weight exhibits a retardation of at least 70% over a period of from 0 to 42 or 43 days. 7. A sustained release formulation according to claim 3 which when administered to a rat subcutaneously at a dosage of 10 mg of octreotide per kg of body weight exhibits an average plasma level of from 2.5 to 6.5 ng/ml over a period of from 0 to 42 days. 8. A sustained release formulation according to claim 3 which when administered to a rabbit intramuscularly at a dosage of 5 mg of octreotide per kg of body weight exhibits an average plasma level of from 3.5 to 6.5 ng/ml. 9. A microparticle according to claim 2 wherein the octreotide is in pamoate salt form. 10. A sustained release formulation comprising a microparticle of claim 9. 11. A microparticle according to claim 2 wherein the surface is substantially free of octreotide. 12. A sustained release formulation comprising a microparticle of claim 1. 13. A microparticle of claim 1 wherein said octreotide is an acetate salt. |
